Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Gifu
Clinical trial register · Japan

Clinical Trials in Gifu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 32 Tokyo 32 Hokkaido 29 Chiba 26 Kanagawa 24
Narrow the registerReset
Recruitment status
Phase
Site location
Fukuoka32 Tokyo32 Hokkaido29 Chiba26 Kanagawa24
All 57 locations
Target enrolment
to

Trials with a site in Gifu

12 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
GlaxoSmithKline
Phase 3
800
Ehime, Fukuoka, Gifu, Hokkaido, Kanagawa, Osaka, Tokyo, Toyama
2026-07-27
Recruiting
GlaxoSmithKline
Phase 3
1,200
Gifu, Kanagawa, Kyoto, Musashino, Yokohama
2025-10-24
Recruiting
GlaxoSmithKline
Phase 3
1,196
Gifu, Mie, Tokyo
2025-10-20
Recruiting
GlaxoSmithKline
Phase 3
981
Kitakyushu-shi, Chiba, Fukuoka, Fukushima, Gifu, Hokkaido, Hyōgo, Ibaraki
2025-06-20
Active, closed
GlaxoSmithKline
Phase 2
307
Chiba, Fukui, Fukuoka, Fukushima, Gifu, Hiroshima, Hokkaido, Hyōgo
2025-02-10
Active, closed
GlaxoSmithKline
Phase 4
1,358
Fukuoka, Gifu, Hiroshima, Hyōgo, Kagawa, Kagoshima, Kanagawa, Kumamoto
2024-04-16
Active, closed
GlaxoSmithKline
Phase 4
336
Gifu, Kagawa, Tokyo
2024-03-20
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
GlaxoSmithKline
Phase 2
284
Fukui, Fukuoka, Gifu, Hiroshima, Kagawa, Kagoshima, Kanagawa, Nagano
2023-01-02
Active, closed
GlaxoSmithKline
Phase 3
110
Aomori, Chiba, Gifu, Hyōgo, Miyagi, Tokyo, Wakayama, Yamanashi
2022-09-06
Active, closed
GlaxoSmithKline
Phase 2
360
Gifu, Hiroshima, Hokkaido, Ishikawa, Kagawa, Kumamoto, Miyagi, Niigata
2021-12-14
Active, closed
GlaxoSmithKline
Phase 3
325
Shibuya-Ku, Aichi, Chiba, Ehime, Fukushima, Gifu, Gunma, Hokkaido
2020-04-02
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 October 2026. https://priyalifescience.com/clinical-trials-japan/city/gifu

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies with a site in Gifu that also match the filters currently applied.

How many clinical trials are recruiting in Gifu?

4 of the 12 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Gifu), 12 studies
PhaseStudiesRecruitingShare
Phase 37458.3%
Phase 23025%
Phase 42016.7%

Most active sponsors

Lead sponsors with the most studies (Gifu)
Lead sponsorStudiesRecruiting
GlaxoSmithKline124
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.